GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Meta] the SURPASS rule is doing its job and people should stop complaining — 52 comments in the full submission. View in context.
3.8k
c/tirzepatide·submitted 2 years ago by u/throwaway_titration

[Meta] the SURPASS rule is doing its job and people should stop complaining

Labbranch of 17 comments

the SURPASS rule is doing its job and people should stop complaining, and here is what changes in practice if it goes ahead. SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category…

Read the full submission and all 52 comments →

This branch

17 comments, started 2 years ago
u/ignacio_vanhecke-38 points·2 years ago

The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.

replysharereportpermalink
[removed]1 point·2 years ago

[removed by moderator]

replysharereportpermalink
u/mod_cold_roommod · c/coldchain1 point·2 years ago

pens and vials are the same molecule, the price is the difference

replysharereportpermalink
load more comments (1) →
u/discount_math_dm1 point·2 years ago

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.

replysharereportpermalink
u/dario_stanescu1 point·2 years ago

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

replysharereportpermalink
u/quiet_moderatorMOD1 point·2 years ago

Trial identifiers corrected in the title. SURMOUNT and SURPASS are different programmes.

replysharereportpermalink
u/customs_seizure_sid1 point·2 years ago

switching from sema is not a dose conversion, there is no clean equivalence

replysharereportpermalink
u/mod_cold_roommod · c/coldchain1 point·2 years ago

Did you come to this from sema, and if so how long was the gap?

replysharereportpermalink
u/elin_varga1 point·2 years ago

Pen or vial? The step sizes available differ and it changes this answer.

replysharereportpermalink
u/emil_wojcik0 points·2 years ago

Pen or vial?

Not sure about this bit. The GIP arm being real does not tell you that it is what caused your particular week.

replysharereportpermalink
u/dexa_twice_yearlybody comp1 point·2 years ago

2.5 is the starter dose and it is not meant to be the dose that works

replysharereportpermalink
u/thyroid_tangent0 points·2 years ago

Are you comparing yourself with the trial mean or with the people who post the most?

replysharereportpermalink
u/throwaway_titrationOP1 point·2 years ago

the constipation profile is genuinely gentler than people expect coming from sema

replysharereportpermalink
u/hub_opssite staff1 point·2 years ago

6kg over 21 weeks, never went past 10mg, and fatigue stayed mild the whole way. Posting because the loud threads are all 15mg.

replysharereportpermalink
u/sten_palacios1 point·2 years ago·edited

6kg over 21 weeks, never went past 10mg, and fatigue stayed mild the whole way.

hub_ops is right that the two molecules are not interchangeable. There is no published conversion and the ones circulating are invented.

replysharereportpermalink
u/throwaway_titrationOP1 point·2 years ago

dual agonist, so the GIP arm is doing something the sema threads will not tell you about

replysharereportpermalink

← back to the whole thread

About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.